Huge Dividend Alert of Rs. 45! P&G Health Confirms Record Date; Buy After Q1FY26 Numbers?

One of the largest producers and distributors of vitamins, minerals, and supplements (VMS) in India is Procter & Gamble Health Limited. It produces and markets products such as Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion. The stock is in the attention of market observers after Procter & Gamble Health Limited revealed its financial results for the first quarter, which concluded on June 30, 2025, along with the date of the final dividend for FY25. Following the Procter & Gamble Health Q1FY26 data, here is the trading advice.

Procter & Gamble Health Record Date For FY25 Final Dividend

"We would like to inform you that the 58th Annual General Meeting of the Company is to be held on Friday, August 29, 2025 at 11 am, in compliance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. With reference to the Notice calling 58th Annual General Meeting submitted today, we would further like to inform you that the record date for the purpose of Annual General Meeting and payment of dividend for the year ended March 31, 2025, if approved by members at the 58th Annual General Meeting - shall be Friday, August 22, 2025," said Procter & Gamble Health in a stock exchange filing.

At its May 29 meeting, the company's board of directors proposed a dividend of Rs. 45 per equity share for the fiscal year that ended on March 31, 2025. If the members agree at the next Annual General Meeting, the dividend will be paid by September 25, 2025, at the latest.

Procter & Gamble Health Q1FY26 Results

In Q1 FY26, Procter & Gamble Health recorded a standalone net profit of Rs 66.18 crore, up 294.4% from Q1 FY25's Rs 16.78 crore.

In the first quarter of FY26, revenue from operations climbed 19.33% YoY to Rs 338.74 crore, while profit before tax (PBT) increased 289.01% to Rs 88.81 crore, up from Rs 22.83 crore in the same quarter of the previous year.

Procter & Gamble Health Target Price

"P&G Health is showing strength near its higher range, trading comfortably above key support at ₹12,800. Immediate resistance lies at ₹13,300, and a breakout above this level could push the stock toward ₹13,800 in the near term. The stock has been holding above short-term moving averages, indicating continued bullish sentiment. RSI is firm, and any dip near ₹12,900-₹13,000 could offer a buying opportunity with a stop-loss at ₹12,750. The overall trend remains positive as long as ₹12,800 holds," commented Riyank Arora, technical analyst at Mehta Equities Ltd.

Disclaimer

The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred to as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.